Altoprev Patent Expiration

Altoprev is a drug owned by Covis Pharma Gmbh. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2018. Details of Altoprev's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6080778 Methods for decreasing beta amyloid protein
Mar, 2018

(6 years ago)

Expired
US5916595 HMG co-reductase inhibitor
Dec, 2017

(6 years ago)

Expired
US6485748 Once daily pharmaceutical tablet having a unitary core
Dec, 2017

(6 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Altoprev is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Altoprev's family patents as well as insights into ongoing legal events on those patents.

Altoprev's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Altoprev's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 23, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Altoprev Generic API suppliers:

Lovastatin is the generic name for the brand Altoprev. 9 different companies have already filed for the generic of Altoprev, with Aurobindo Pharma Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Altoprev's generic

Alternative Brands for Altoprev

Altoprev which is used for decreasing A-beta production in patients at risk of or exhibiting symptoms of Alzheimer's disease., has several other brand drugs using the same active ingredient (Lovastatin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Abbvie
Advicor


Apart from brand drugs containing the same ingredient, some generics have also been filed for Lovastatin, Altoprev's active ingredient. Check the complete list of approved generic manufacturers for Altoprev





About Altoprev

Altoprev is a drug owned by Covis Pharma Gmbh. It is used for decreasing A-beta production in patients at risk of or exhibiting symptoms of Alzheimer's disease. Altoprev uses Lovastatin as an active ingredient. Altoprev was launched by Covis in 2002.

Approval Date:

Altoprev was approved by FDA for market use on 26 June, 2002.

Active Ingredient:

Altoprev uses Lovastatin as the active ingredient. Check out other Drugs and Companies using Lovastatin ingredient

Treatment:

Altoprev is used for decreasing A-beta production in patients at risk of or exhibiting symptoms of Alzheimer's disease.

Dosage:

Altoprev is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20MG TABLET, EXTENDED RELEASE Prescription ORAL
10MG TABLET, EXTENDED RELEASE Discontinued ORAL
40MG TABLET, EXTENDED RELEASE Prescription ORAL
60MG TABLET, EXTENDED RELEASE Prescription ORAL